Lidocaine Accord Healthcare (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve and cardiac cells, preventing sodium influx during depolarization. This stops the generation and spread of action potentials, resulting in loss of sensation in the treated area and stabilisation of abnormal cardiac electrical activity.

The appropriate dose of lidocaine is determined by the prescribing clinician based on the intended indication, route of administration, patient weight, age, and clinical condition. Dosage recommendations are provided in the product’s prescribing information and must be individualized.

Safety data for lidocaine in pregnancy are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any potential risk to the fetus. Lidocaine is excreted in breast milk; caution is advised when administering to nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Lidocaine is a medium‑duration amide‑type local anesthetic with a rapid onset, making it suitable for many infiltration and nerve‑block procedures. Compared with shorter‑acting agents like procaine, lidocaine provides longer analgesia, while agents such as bupivacaine offer even longer duration but have a higher risk of cardiotoxicity.

Lidocaine Accord Healthcare should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations to maintain sterility and potency.

Lidocaine is administered by infiltration into the target tissue, as a regional nerve block, or intravenously for anti‑arrhythmic therapy. The route, injection technique, and volume are determined by the clinician based on the specific clinical indication and patient factors.

Serious risks include systemic toxicity manifesting as methemoglobinemia, severe cardiac conduction disturbances (e.g., bradycardia, heart block), seizures, respiratory depression, and anaphylactic reactions. Prompt recognition and supportive management are essential if toxicity occurs.

Lidocaine should be avoided in patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, in those with severe hepatic impairment, and in individuals with certain cardiac conduction disorders unless specifically indicated and closely monitored.